The potential use of human Decidua-derived mesenchymal stem cells (DMSCs) as a platform to carry mesoporous silica nanoparticles in cancer therapy has been investigated. Two types of nanoparticles were evaluated. The nanoparticles showed negligible toxicity to the cells, a fast uptake and a long *Manuscriptrevised2 Click here to view linked References 2 retention inside them. Nanoparticle location in the cell was studied by colocalization with the lysosomes. Moreover, the in vitro and in vivo migration of DMSCs towards tumors was not modified by the evaluated nanoparticles.
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Finally, DMSCs transporting doxorubicin-loaded nanoparticles were capable of inducing cancer cell death in vitro.
Introduction
The use of nanotechnology for drug delivery is nowadays changing the fields of biotechnology and biomedicine, allowing the incorporation of multiple therapeutic, sensing and targeting agents into nanoparticles (NPs). [1, 2] Those NPs can be manufactured with a great variety of compositions and/or structures. [3] Among the different types of NPs, mesoporous silica NPs offer superior structural properties compared to other NPs, such as, large surface area and pore volume, tunable pore sizes, colloidal stability and robustness that allows straightforward functionalization of the silica walls. [4] [5] [6] NPs have been widely investigated as carriers for targeted drug delivery to cancer cells because they can overcome several inconveniences of systemic drug administration, such as poor solubility and limited stability of several drugs and side-effects due to non-specific uptake of the cytotoxic drugs by healthy cells. [7] [8] [9] In this sense, a key aspect of this technology is that NPs can be targeted and delivered into the tumors, which can be achieved by either passive targeting, through the enhanced permeability and retention (EPR) effect, [10, 11] or active targeting, through the functionalization of nanoparticle surface with certain affinity ligands that would be specifically recognized by the targeted diseased cells. [12] However, the recent progress in nanotechnology has not achieved the expected results in improving drug targeting, [13, 14] highlighting the need of a better localization of the nanoparticles towards the tumor sites.
Human mesenchymal stem cells (MSCs), which are multipontent progenitors cells that maintain and regenerate connective tissues, [15] present migratory properties towards tumors. Those inherent tumor tropism and migratory properties suggest their possible use as carriers of NPs to isolated tumors and metastasic diseases. [16, 17] A particular type of MSCs, those from the decidua of human placenta, have shown migratory capacity towards tumors in vitro, as well as in a preclinical model of breast tumors. [18] Although the driving force for DMSCs to migrate into tumor sites is unknown, it is already well known that human MSCs have high tropism towards tumors. [19] The inflammatory tumor microenvironment enables human MSCs to specifically home to tumor tissues.
Several factors such as cytokines, growth factors, receptors, extracellular matrix and inflammation factors appear to be involved in this migration capacity. [20, 21] More interestingly, DMSCs have been observed to inhibit the growth of primary tumors and the development of new tumors [18] . These observations, together with the facts that DMSCs are easy to obtain and constitute a homogeneous population, inspired the idea of using them as therapeutic agents and as cellular vehicles of nanoparticles towards tumors.
The aim of the present work is to exploit the benefits of the chemistry and 2. Experimental Section.
Fabrication and characterization of dye-doped NPs.
NPs were synthesized by modifying previous methods. [23] Briefly, APTES-dyes were synthesized by labeling 3-aminopropyl triethoxysilane (APTES) with active groups of dyes. For example, APTES (2.2 µL) was labeled with 1 mg of fluorescein isothiocyanate (FITC) in 100 µL of ethanol solution. The reaction mixture was stirred at room temperature for 2 h. Separately, cetyltrimethylammonium bromide (CTAB) (1 g) was dissolved in 480 mL of deionized water and 3.5 mL of 2M NaOH were added with magnetic stirring. The mixture was heated to 80 ºC and left for 30 min. Then, 5 mL of tetraethyl orthosilicate (TEOS) for negatively-charged NPs (neg-NPs), or a mixture of TEOS and APTES (4.5 and 0.5 mL, respectively), for positively-charged NPs (pos-NPs), was added slowly during 20 min, then the particles were left at 80 ºC under stirring for 2 h. The resulting particles were collected by centrifugation and then washed three times with deionized water and ethanol, respectively. The surfactant template was removed by ion exchange using an extracting solution of NH 4 NO 3 (10 mg/mL) in EtOH (95 %). The particles were suspended in that medium and magnetically stirred at 75 ºC overnight. The particles were centrifuged and washed three times with deionized water and ethanol. Surfactant removal was confirmed by thermogravimetric analysis.
All the reagents used for the synthesis of NPs were commercial products (Sigma-Aldrich, Spain) and were used without further purification. by the cell dilution folds due to cell division.
Intracellular fate of NPs.
For the co-localization of NPs and lysosomes, the cells were incubated with 200 g/mL particles for 2 h. The cells were washed twice with PBS solution. Then, lysosomes were stained with the Cell Tracker® Lysosome staining kit following the manufacturer protocol (AAT Bioquest, Inc, USA). The cells were washed twice with PBS, and then fresh medium was added. The cells were fixed and stained with DAPI as previously described. Fluorescence microscopy was performed with an Evos® FL Cell Imaging System.
Cytotoxicity of NPs.
The cytotoxicity of NPs was evaluated using the following standard protocols:
Lactate dehydrogenase (LDH) activity test: Extracellular LDH activity was measured in the media using the kit for Quantitative determination of LDH (Spinreact, Spain). DMSCs were incubated with NPs for 24 h at different concentrations. Then, the culture medium was collected for measuring the extracellular LDH activity. The LDH activity was directly measured by spectrophotometer at 340 nm in the culture medium following the manufacturer protocol.
The MTS reduction assay was performed using a commercial assay and following the manufacturer´s protocol (CellTiter® Aqueous One Solution Cell Proliferation Assay). Briefly, DMSCs were incubated with various concentrations of NPs for 2 h (n=3). The medium was replaced with 600 µL culture medium including MTS, and the incubation proceeded for 3 h.
The medium was then removed, and its absorption at 490 nm was measured using a microplate reader.
Tissue homogenates from NMU-induced mammary tumors.
N-nitroso-N-methylurea (NMU) tumors were induced in 45-day-old SpragueDawley female rats according to our previously published protocol. [25] Concisely, NMU (Sigma-Aldrich, Spain) was administered once a week during two weeks by intra-peritoneal injection at a concentration of 5 mg/100g rat body weight. As well, metoclopramide (0.125 mg/L) was administered in the drinking water. Animals were palpated weekly for the detection of mammary tumors.
The tumors were disected out from the animals, immediately frozen in liquid nitrogen and subsequently stored at -80 ºC until use.
Homogenates were performed at 4 ºC as we previously described. [18] The protein concentration was measured using the Lowry protein assay kit (Biorad, Spain) following the manufacturer´s instructions.
Transwell assay.
The in vitro effect of mammary tumor homogenate on DMSCs migration capacity was determined using Millicell culture plate inserts with 8 μm pore polycarbonate membranes (Merk Millipore, Spain) in 24-well plates. Briefly, 1.5x10 5 DMSCs in 300 µL of serum-free DMEM were seeded in the insert. 
In vivo migration.
To evaluate the in vivo migration capacity of NP loaded DMSCs, cells were incubated with pos-NPs as previously described. After washing non-internalized NPs, 10 6 cells were injected into the circulation through the tail-vein of SprawDawley rats with NMU-mammary tumors. Seventy-two hours later, rats were anesthetized, and mammary tumors were removed and stored at -80ºC until use. Frozen tissue was sectioned in the cryostat, treated with Sudan Black to removed self-fluorescence following the manufacturer´s instructions, the nuclei were stained with DAPI for 1 min and sections were mounted with Vectashield and the tissue sections were visualized by fluorescence microscopy. 
In vitro experiments with doxorubicin-loaded NPs

Results and Discussion.
In order to evaluate DMSCs as potential carriers of NPs, mesoporous silica NPs (neg-NPs and pos-NPs) were synthesized according to a modified Stöber method [23] . Both types of NPs were covalently labeled with fluorescein by cocondensation during nanoparticle synthesis in order to be able to follow the fate of the NPs in contact with cells by fluorescence microscopy. Regarding particle morphology, SEM micrographs showed NPs, neg-NPs and pos-NPs, with spherical shape. Additionally, well-ordered mesoporous channels could be appreciated in the corresponding TEM micrographs (Figure 1 ). In fact, typical XRD patterns of MCM-41 type materials were observed in all cases, with the three characteristic maxima (100), (110) This is of great value for subsequent experiments because it is very important to have as much NPs as possible incorporated into cells.
Once toxicity was found not to be an issue, the next step was to evaluate the endocytosis process, studying how long the NPs remain inside the cells Once the NPs have been internalized, the next important parameter to consider is the retention time of the particles in the cells. According to previous studies by our group [18] , it was found that 3 days is the necessary time for the DMSCs to reach the tumor tissues in an in vivo model, so the particles should remain in the cells a minimum of 3 days. The procedure to evaluate the retention capacity of the particles in DMSCs was similar to the uptake experiment, that is, cells were incubated with 200 µg/mL of both neg-and posNPs for 2 h, then washed and cultured for up to 5 days. Figure 3c shows the normalized fluorescence intensity percentage of the cells at different culturing times, being almost constant for the neg-NPs, which means that those NPs were retained in the cytoplasm. Pos-NPs fluorescence was kept unchanged at the initial stages, but after 1 day the intensity increased up to ca. 140 %. This could be explained by a slow uptake of membrane-adhered nanoparticles due to interactions between pos-NPs and negatively-charged phospholipids at the cell membrane. [28] This means that in terms of retention capacity, a greater amount of particles were observed in the group of pos-NPs than in the negNPs. Most importantly, in all cases, NPs were still retained in the cells at day 5.
Taking into account that it takes around 3 days for the cells to reach the tumor in the in vivo model previously evaluated, [18] those results guarantee that our
NPs will be still in the cells when reaching the tumor tissue, validating our initial hypothesis of using DMSCs as carriers of nanoparticles.
Once internalization and retention of NPs into living mesenchymal cells were validated, the next step was exploring the location of internalized NPs in the cells. NPs are normally transported to the endo-lysosomal system after internalization, and the ability of the NPs to escape from the lysosomes is an important parameter regarding the stability of the NPs. [17] A co-localization study was performed in DMSCs with internalized NPs by staining the cell lysosomes (Cell Navigator® Lysosome staining kit) and comparing the location within the cells of lysosomal red fluorescence and NPassociated green fluorescence. We observed that NPs were located inside lysosomes just after internalization ( Figure S5 ), independently of their surface charge. However, after 3 days, the location of NPs inside the cells was different for pos-NPs and neg-NPs (Figure 3d ). In neg-NPs, the fluorescence due to NPs was co-localized within the lysosomes, which indicates that neg-NPs were not able to escape the lysosomes in that time. On the other hand, fluorescence from pos-NPs does not match the fluorescence of the cell lysosomes at day 3, which shows that these NPs had escaped the lysosomes, probably by a chargedependent mechanism previously described in the literature. 
